Purpose

In this study we will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for people with intermediate-risk prostate cancer receiving standard stereotactic body radiotherapy (SBRT).

Condition

Eligibility

Eligible Ages
Between 18 Years and 99 Years
Eligible Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Biopsy proven grade group 2 or 3 (GS 3+4 or GS 4+3) cancer with all pattern 4 found only in the MRI target - Gland size ≤ 80 cc - Prostate MRI < rT3b disease - IPSS < 20 - No contraindication to IRE, RT, anesthesia, or transperineal procedure

Exclusion Criteria

  • Any Grade Group ≥4 disease, or any cribriform and/or intraductal carcinoma - Evidence of nodal or /metastatic disease on MRI and/or PSMA PET/CT - Unfit for general anesthesia, or contraindication/hypersensitivity to required neuromuscular blocking agents - Active urinary tract infection (UTI) at the time of IRE or biopsy; must be treated and resolved prior to proceeding - Actively bleeding, known bleeding disorder, or inability to interrupt anticoagulants/antiplatelet therapy as clinically indicated for biopsy/IRE safety - Any history of cardiac arrhythmia or epilepsy, or recent myocardial infarction, consistent with NanoKnife contraindication statements - Presence of an implanted pacemaker/defibrillator or other active implanted electronic device, or other device-related contraindications per current NanoKnife labeling/user manual - Inability to undergo pelvic MRI - Prior treatment of prostate cancer including androgen deprivation therapy, focal therapy, radiation therapy, or prostatectomy - Current or intended use of androgen deprivation therapy

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
IRE Boost Arm
Participants will receive Irreversible Electroporation
  • Device: NanoKnife System
    The NanoKnife System is the device that is used for Irreversible Electroporation/IRE. The NanoKnife Generator is a microprocessor-controlled low energy direct current (LEDC) irreversible electroporation device.
  • Radiation: Stereotactic Body Radiation Therapy
    Radiation-based treatment intensification involves delivery of a boost to the dominant intraprostatic lesion (DIL) to a higher dose than the surrounding prostate tissue using external beam radiation therapy.
    Other names:
    • SBRT
Active Comparator
RT Boost Arm
Participants will receive Radiation Therapy and will serve as the control arm
  • Radiation: Stereotactic Body Radiation Therapy
    Radiation-based treatment intensification involves delivery of a boost to the dominant intraprostatic lesion (DIL) to a higher dose than the surrounding prostate tissue using external beam radiation therapy.
    Other names:
    • SBRT

Recruiting Locations

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey 07920
Contact:
Himanshu Nagar, MD
212-639-6478

Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)
Middletown, New Jersey 07748
Contact:
Himanshu Nagar, MD
212-639-6478

Memorial Sloan Kettering at Bergen (Limited Protocol Activities)
Montvale, New Jersey 07645
Contact:
Himanshu Nagar, MD
212-639-6478

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
Commack, New York 11725
Contact:
Himanshu Nagar, MD
212-639-6478

Memorial Sloan Kettering at Westchester (Limited Protocol Activities)
Harrison, New York 10604
Contact:
Himanshu Nagar, MD
212-639-6478

Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York 10065
Contact:
Himanshu Nager, MD
212-639-6478

Memorial Sloan Kettering at Nassau (Limited Protocol Activities)
Uniondale, New York 11553
Contact:
Himanshu Nagar, MD
212-639-6478

More Details

Status
Recruiting
Sponsor
Memorial Sloan Kettering Cancer Center

Study Contact

Himanshu Nagar, MD
212-639-6478
nagarh1@mskcc.org

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.